Next-Generation Immunotherapy: Integrating Cellular Therapies, Vaccines, and Nanomedicine

Next-Generation Immunotherapy: Integrating Cellular Therapies, Vaccines, and Nanomedicine
Details
Research Project Number:
RP-NASS-2026-013
Academic Lead:
Dr. Shikha Sharma
Co-academic leads:
Dr. Payal Bhatnagar, Dr. Neeraj K. Sethiya
Deadline:
December 30, 2026
Dr. Shikha Sharma

Name: Dr. Shikha Sharma

Affiliation: Lords University

E-Mail: sharma.shikha631@gmail.com

Google Scholar: https://scholar.google.com/citations?user=GUL0yBMAAAAJ&hl=en

Orcid: https://orcid.org/0000-0002-9717-7819

Research Interests: pharmaceutical sciences, medicinal chemistry, and nanotechnology-driven drug delivery systems, design, synthesis, and biological evaluation of novel heterocyclic compounds for therapeutic applications, particularly in cancer, diabetes, microbial infections, and neurological disorders.

Research objectives:

Recent breakthroughs in immunotherapy have remarkably changed the treatment of diseases, including those in the areas of oncology, infectious diseases, and autoimmune diseases. The latest trends in research and developments are centered on the following areas of immunotherapy: immune checkpoint inhibitors (such as PD-1/L1 and CTLA-4 inhibitors), CAR-T cell therapy, cancer vaccines, and adoptive cell therapy approaches. Other emerging areas that are under investigation nowadays are personalized immunotherapy approaches, neoantigen vaccines, bispecific antibodies, oncolytic viruses, and the use of nanotechnology for immunomodulation. There is also a recent focus of research work emphasizing the need for combination therapy (chemo-immunotherapy, radiation-immunotherapy, and nanocarriers).

Keywords:

  • Immunotherapy
  • Immune checkpoint inhibitors
  • PD-1/PD-L1
  • CTLA-4
  • CAR-T cell therapy
  • Cancer vaccines
  • Adoptive cell therapy
  • Personalized immunotherapy
  • Neoantigen vaccines
  • Bispecific antibodies
  • Oncolytic viruses
  • Nanotechnology
  • Immunomodulation
  • Combination therapy
  • Chemo-immunotherapy
  • Radio-immunotherapy;
  • Nanocarriers

Expected Outcomes:

Academic: Peer-reviewed publications

Co-academic leads:
1-2.png

Dr. Payal Bhatnagar

Affiliation: Department of Pharmaceutical Technology, School of Pharmacy, IMU University, Kuala Lumpur 57000, Malaysia

E-Mail: payalbhatnagar2020@gmail.com

Website: https://academic-members.imu.edu.my/staff_info.php?user=515

Research Interests: Wound dressing, Regenerative materials, Novel drug delivery system, Controlled drug release, Cosmetics

1-3.png

Dr. Neeraj K. Sethiya

Affiliation: Faculty of Pharmacy, School of Pharmaceutical and Population Health Informatics, DIT University, Dehradun 248009, Uttarakhand, India

E-Mail: drnspharma@gmail.com

Website: https://scholar.google.com/citations?user=rizDJQMAAAAJ&hl=en

Research Interests: Herbal Drug, Technology Phytochemistry, Pharmacology Pharmacognosy, Natural Products and Plant Tissue Culture

Trends in Immunotherapy (TI)

JBMS Journal Cover
ISSN:
2573-5985 (Online)
Frequency:
Quarterly (Mar, Jun, Sep, Dec)
Indexing: Scopus, ROAD, ResearchGate, CNKI Scholar, Crossref, Google Scholar, Scilit, Worldcat

Publisher: UK Scientific Publishing Limited

Submit an Article

Note:
-  Manuscripts under this research project are intended for publication in the above journals.

-  Academic Lead, Co-AL, and potential contributors may choose the appropriate journal for submission according to the needs. When submitting, please select “Research Project of NASS”​ in the OJS (Open Journal Systems) backend.

- For any questions (e.g., paper submission details, process), please contact :
   Research Project Coordinator: Lorena
   Email: lorena@nassg.net